Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595814 · ClinicalTrials.gov registry record
Global Non-interventional Heart Failure Disease Registry
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- 18,805
- Enrollment target
NCT02595814 is a clinical trial that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 18,805 participants.
The verdict
NCT02595814 was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- 18,805 participants
- Enrollment target
Study Summary
The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,805 participants |
| Start Date | 2014-07-23 |
| Est. Completion | 2018-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595814
The ClinicalTrials.gov registry entry for NCT02595814 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 18,805 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02595814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595814 about?
NCT02595814 is a clinical study titled "Global Non-interventional Heart Failure Disease Registry". The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designe...
What is the current status of trial NCT02595814?
This trial is currently terminated. The enrollment target is 18,805 participants. The study started on 2014-07-23. Estimated completion is 2018-03-31.
Who is sponsoring clinical trial NCT02595814?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.